I’m confused with the FDA hold in that the hold itself was on safety. Now to my knowledge all the material regarding safety was supplied earlier this year. After submission of the safety data FDA then requested some future HIV trial plans. I just don’t understand why management didn’t challenge that in that the future trial plans has nothing to do with the safety aspects of Leronlimab itself.

If my understanding is incorrect please feel free to correct me.